Whats changed?21 Sep 2020 12:43
Answer is nothing.... we are still waiting for tests to be validated.
If they had failed we would have been told, if they had completed validation we would have been told.
Avacta remains focused on the much larger opportunity of the saliva-based coronavirus antigen rapid test that we are developing with Cytiva and which is now in the process of technology transfer to our manufacturing partners. The excellent analytical performance of the ELISA test is very encouraging with regards to the anticipated clinical performance of the rapid test and I look forward to starting the clinical validation with the first pilot batch of rapid tests as soon as possible."